A Randomized, Double‐Blind, 2‐Treatment, 2‐Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU /Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration
Molecular Genetics & Genomic Medicine · 2025
DOI: 10.1002/mgg3.70111 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Molecular Genetics & Genomic Medicine, 2025. Verfasst von Eungu Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea. Hauptthemen laut MEDLINE: Glucosylceramidase. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ISU Abxis.
Abstract (Originalsprache)
Background
Imiglucerase (Cerezyme; Sanofi, Paris, France), an analogue of β‐glucocerebrosidase produced by recombinant DNA technology, has been a safe and effective treatment for Gaucher disease (GD) for over 25 years. A new imiglucerase, Abcertin (Seongnam‐si, Gyeonggi‐do, Republic of Korea) has shown a similar safety and efficacy profile in previous clinical studies. This study compared the pharmacokinetics, immunogenicity, safety, and tolerability to EU‐sourced Cerezyme following a single 60 IU/kg dose.
Methods
This phase 1, single‐center, randomized, double‐blind, two‐way crossover study enrolled 36 healthy volunteers aged 18–45 years. Participants were randomly assigned to receive either Abcertin or Cerezyme in a predetermined sequence.
Results
Abcertin reached peak plasma concentrations at a median t max of 61 min (range: 40–121 min). The mean C max , AUC 0–last , and AUC 0–inf were 115.4 mU/mL, 12,190 min·mU/mL, and 12,210 min mU/mL, respectively, indicating bioequivalence to Cerezyme. The mean t ½ , CL, and V z were 6.88 min, 376.7 mL/min, and 3.62 L, respectively, and were comparable between the two treatments. One participant in the Cerezyme group developed anti‐drug antibodies, which were non‐neutralizing A total of 24 subjects experienced treatment‐emergent adverse event (TEAE). The most common TEAE was headache (3 in the Abcertin group and 5 in the Cerezyme group), followed by general disorders and administration site condition (3 in Abcertin group and 5 in Cerezyme group). Two participants in the Cerezyme sequence experienced severe TEAEs: one had a urinary tract infection, and the other developed urticaria, which leading to study withdrawal.
Conclusion
Abcertin demonstrated pharmacokinetic equivalence to Cerezyme, with a comparable safety, immunogenicity, and tolerability profile. These findings support its potential as an affordable biosimilar for GD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.
- Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Scientia Clinical Research (SCR), Randwick, New South Wales, Australia.
- ISU ABXIS Co., Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea.
- Department of Pediatrics, CHA University School of Medicine, Bundang CHA Medical Center, Seongnam, Republic of Korea.
- Medical Genetics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Eungu Kang, Beom Hee Lee
Förderung
- ISU Abxis
Zitieren
APA
Kang, E., Kim, D., Hwang, S., Lemech, C., Wharton, J., Lee, Y., Yoo, H. W., & Lee, B. H. (2025). A Randomized, Double‐Blind, 2‐Treatment, 2‐Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU /Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70111
Vancouver
Kang E, Kim D, Hwang S, Lemech C, Wharton J, Lee Y, et al. A Randomized, Double‐Blind, 2‐Treatment, 2‐Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU /Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration. Molecular Genetics & Genomic Medicine. 2025. doi:10.1002/mgg3.70111
BibTeX
@article{Kang2025,
author = {Kang, Eungu and Kim, Dohyung and Hwang, Soojin and Lemech, Charlotte and Wharton, Jessica and Lee, Yongyoon and Yoo, Han Wook and Lee, Beom Hee},
title = {A Randomized, Double‐Blind, 2‐Treatment, 2‐Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU /Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration},
journal = {Molecular Genetics & Genomic Medicine},
year = {2025},
doi = {10.1002/mgg3.70111}
}
EUVIMED